Failure to Disclose Employee Notes Constitutes Inequitable Conduct
Client Alert | 1 min read | 02.20.08
In Monsanto Co. v. Bayer Bioscience N.V., (No. 07-1109; January 25, 2008) a Federal Circuit panel affirms a district court’s decision that a patent is unenforceable. Bayer disclosed an abstract relating to a poster shown at a scientific conference. Bayer did not disclose detailed notes that one of its employees took regarding the poster.
The panel’s analysis focuses on whether or not the district court made a clear error in determining the failure to disclose the notes, which were not prior art, amounted to inequitable conduct. Because the notes clearly and convincingly refute the position Bayer took in opposing the Examiner’s rejection, says the panel, the notes are material and should have been disclosed. But the panel is also careful in pointing out that not all internal documents of potential relevance must be submitted. In this case, however, the notes are material because they directly contradict Bayer’s arguments made in support of patentability.
With regard to intent, the panel points out that “[i]ntent is easily inferred when, as here, an applicant makes arguments to the PTO that it knows, or obviously should have known, are false in light of information not before the examiner, and the applicant knowingly withholds that additional information.” The district court’s determination that Bayer failed to offer a credible explanation for withholding the notes is not disturbed.
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today